 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Diabetes-related stocks such as Isens and Peptron are on the rise.
On the 18th, iSense closed the transaction at 32,000 won, up to the price limit (29.82%). Peptron and Dongwoon Anatech also rose 26.4% and 17.28%, respectively. Dongwoon Anatech has increased six times in the past month. Foreigners and institutions bought Peptron intensively, and individuals flocked to iSense and Dongwoon Anatech.
These companies, which have been trapped in the box pattern for a long time, have shifted to a surge since Big Pharma began to pay attention to the diabetes market. "Major pharmaceutical companies around the world are entering the diabetes market as it has been revealed that diabetes treatments are also effective in losing weight," a securities industry source said.
Peptron, which is developing diabetes and obesity treatments, is expected to transfer technology. It is known that it has received "term sheet" for diabetes and obesity treatments from global pharmaceutical companies. A term sheet is an agreement signed to discuss detailed conditions just before a technology transfer contract.
Dongwoon Anatech, a semiconductor designer, is developing a product that can measure blood sugar with saliva. Fine current control technology used in semiconductors can measure blood sugar without blood collection.
ISENSE has completed the development of a continuous blood glucose meter and will be released in September. I am planning to go to Europe next year. Templeton Investment, a global value investment manager, recently increased its stake in iSense to 7.32%.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
